Replies to post #40426 on $heff's $tation of $tocks & $olid DD

[jrbritt]

This is good news. Although the Cerezyme supply has been corrected the ability to switchover is VITAL to success of UPLYSO because the market has been exposed to Cerezyme for some time. This allows Protalix to not just limit their market to new patients but to those already using Cerezyme. It is always a challenge to break into an established market but with the results from the switchover trial, at least they aren't "behind the 8-ball" so to speak and all patients are potentially up for grabs. Sales will depend on PLX developing an effective market plan - as all the data/safety results seem on par, if not slightly better is some aspects, with competitors.

Good luck to all!




Disclosure: I am holding a small position in PLX and will be holding through the decision.

[read_this_n0w]

OXGN Chart .15 two to three potential phase III cancer trials, market cap 20mln

SNSS market cap 100mln+ ?
Buy here and keep 6-12 months.

Recent news:

OXiGENE will provide ZYBRESTAT to National Cancer Institute (NCI) for an NCI-sponsored study conducted by the Gynecologic Oncology Group (GOG), an organization dedicated to clinical research in the field of gynecologic cancer. The aim of the trial will be to determine if the combination of ZYBRESTAT and bevacizumab will enhance anti-tumor effects and further delay tumor progression when compared to bevacizumab alone.OXiGENE anticipates that investigators will initiate enrollment in this Phase II study in the first quarter of 2011. The primary endpoint of the study will be progression-free survival, with results expected to become available in early 2013.

Thanks chris.

short interest

01/31/2011 1,770,018 (34.50) 2,468,672 1.00
01/14/2011 2,702,122 0.98 1,215,805 2.22
12/31/2010 2,675,999 1.96 3,319,285 1.00
12/15/2010 2,624,535 34.07 1,151,030 2.28
11/30/2010 1,957,610 (20.63) 2,083,833 1.00
11/15/2010 2,466,563 (11.96) 2,298,385 1.07